Nasdaq · CIK 0001756262
TMDX TransMedics Group, Inc.
Insider trading from SEC Form 4. Last filing 30 d ago. Close $77.87 on Oct 9, 2026, +26% from the 52-week low and -48% from the high.
In brief
TransMedics Group, Inc. (TMDX) has 102 SEC Form 4 filings on file from 15 insiders, the latest filed on Sep 14, 2026. In the last 90 days insiders made 1 open-market buy worth $109k and 0 open-market sells worth $0, net +$109k.
65 open-market trades have been scored at TMDX. The newest: David Weill (director) bought $109k of stock on Sep 11, 2026, filed Sep 14, 2026, scored 36 (weak). The largest of the 50 shown: Tamer I Khayal (Chief Commercial Officer) sold $8.6M on May 1, 2024, scored 40 (moderate), under a 10b5-1 plan. 5 insiders sold within 14 days of each other around Mar 4, 2026.
25 Form 144 notices of planned sales are on file, the latest filed Jun 15, 2026.
Last 90 days
Net insider value
+$109k
more bought than sold
Buys
1
$109k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
TMDXOct 9, 2026 · close 77.87
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at TransMedics Group, Inc., scored: the newest 50 of 65.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | David Weill director buy | $109k 1,336 shares | +9% | +32% from low-45% from high | |
| 31Weak | Thomas James Gunderson director sell | $722k 9,624 shares | -37% | +22% from low-50% from high | |
| 52Moderate | Stephanie Lovell director sell | $178k 1,193 shares | -29% | +129% from low-2% from high | |
| 38Weak | David Weill director sell | $524k 3,571 shares | -23% | +129% from low-2% from high | |
| 46Moderate | Nicholas Corcoran See remarks sell | $413k 2,966 shares | -9% | +128% from low-2% from high | |
| 67Notable | Gerardo Hernandez Chief Financial Officer sell | $1.1M 7,611 shares | -51% | +128% from low-2% from high | |
| 40Moderate | Anil P. Ranganath See remarks sell | $120k 864 shares | -6% | +128% from low-2% from high | |
| 48Moderate | Gerardo Hernandez Chief Financial Officer sell | $128k 920 shares | -6% | +144% from low-8% from high | |
| 46Moderate | David Weill director sell | $693k 5,000 shares | -29% | +147% from low-7% from high | |
| 37Weak | Anil P. Ranganath See remarks sell | $436k 3,000 shares | -18% | +157% from low0% from high | |
| 54Moderate | Waleed H Hassanein President & CEO buy | $1.0M 8,775 shares | +2% | +100% from low-21% from high | |
| 19Weak | Edward M Basile director sell | $540k 4,142 shares | -59% | +137% from low-6% from high | |
| 54Moderate | Waleed H Hassanein President & CEO buy | $2.0M 16,875 shares | +4% | +109% from low-28% from high | |
| 18Weak | Edward M Basile director sell | $520k 4,143 shares | -59% | +127% from low-23% from high | |
| 33Weak | Anil P. Ranganath See remarks sell | $96k 686 shares | -5% | +146% from low-16% from high | |
| 35Weak | Edward M Basile director sell | $632k 5,000 shares | -64% | +127% from low-23% from high | |
| 32Weak | David Weill director sell | $91k 732 shares | -6% | +119% from low-25% from high | |
| 29Weak | Edward M Basile director sell | $694k 6,000 shares | -89% | +97% from low-33% from high | |
| 27Weak | Tamer I Khayal Chief Commercial Officer sell | $184k 2,407 shares | -6% | - | |
| 0Weak | Tamer I Khayal Chief Commercial Officer sell | $87k 1,083 shares | -5% | - | |
| 0Weak | Tamer I Khayal Chief Commercial Officer sell | $94k 1,084 shares | -5% | - | |
| 0Weak | Tamer I Khayal Chief Commercial Officer sell | $131k 1,458 shares | -7% | - | |
| 27Weak | Edward M Basile director sell | $564k 6,750 shares | -90% | - | |
| 0Weak | Tamer I Khayal Chief Commercial Officer sell | $89k 1,083 shares | -5% | - | |
| 20Weak | Waleed H Hassanein President & CEO sell | $1.1M 8,625 shares | -12% | - | |
| 35Weak | Waleed H Hassanein President & CEO sell | $1.2M 8,625 shares | -12% | +287% from low-2% from high | |
| 61Notable | Edward M Basile director sell | $165k 1,193 shares | -62% | +268% from low-5% from high | |
| 16Weak | Stephen Gordon Chief Financial Officer sell | $280k 2,060 shares | -9% | +264% from low-6% from high | |
| 16Weak | Tamer I Khayal Chief Commercial Officer sell | $394k 2,960 shares | -12% | +264% from low-6% from high | |
| 67Notable | Stephen Gordon Chief Financial Officer sell | $2.8M 20,000 shares | -86% | +287% from low-0% from high | |
| 46Moderate | David Weill director sell | $169k 1,193 shares | -10% | +287% from low-0% from high | |
| 35Weak | Waleed H Hassanein President & CEO sell | $1.2M 8,625 shares | -12% | +271% from low0% from high | |
| 49Moderate | David Weill director sell | $325k 2,500 shares | -18% | +254% from low-2% from high | |
| 55Moderate | Tamer I Khayal Chief Commercial Officer sell | $6.9M 63,260 shares | -87% | +220% from low0% from high | |
| 54Moderate | Edward M Basile director sell | $930k 7,157 shares | -86% | +246% from low-4% from high | |
| 51Moderate | Nicholas Corcoran See Remarks sell | $419k 3,222 shares | -13% | +261% from low0% from high | |
| 37Weak | Stephen Gordon Chief Financial Officer sell | $1.9M 15,000 shares | -39% | +261% from low0% from high | |
| 40Moderate | Waleed H Hassanein President & CEO sell | $3.9M 30,000 shares | -33% | +261% from low0% from high | |
| 27Weak | Tamer I Khayal Chief Commercial Officer sell | $759k 5,839 shares | -37% | +261% from low0% from high | |
| 35Weak | James R Tobin director sell | $1.5M 12,025 shares | -6% | +248% from low0% from high | |
| 50Moderate | Waleed H Hassanein President & CEO sell | $8.0M 68,444 shares | -53% | +220% from low0% from high | |
| 40Moderate | Tamer I Khayal Chief Commercial Officer sell | $8.6M 78,036 shares | -107% | +220% from low0% from high | |
| 35Weak | James R Tobin director sell | $1.6M 15,040 shares | -7% | +220% from low0% from high | |
| 21Weak | Waleed H Hassanein President & CEO sell | $380k 4,000 shares | -5% | +139% from low-9% from high | |
| 35Weak | Waleed H Hassanein President & CEO sell | $1.1M 12,000 shares | -14% | +160% from low-0% from high | |
| 40Moderate | Tamer I Khayal Chief Commercial Officer sell | $1.8M 19,900 shares | -67% | +145% from low-6% from high | |
| 27Weak | Tamer I Khayal Chief Commercial Officer sell | $802k 10,000 shares | -33% | +105% from low-22% from high | |
| 37Weak | Stephen Gordon Chief Financial Officer sell | $1.1M 15,000 shares | -39% | +100% from low-24% from high | |
| 48Moderate | Stephen Gordon Chief Financial Officer sell | $167k 1,903 shares | -8% | +128% from low-13% from high | |
| 5Weak | Tamer I Khayal Chief Commercial Officer sell | $124k 1,417 shares | -5% | +128% from low-13% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 15, 2026 | THOMAS GUNDERSON Director | 9,624 0.03% of outstanding | $722k | Jun 15, 2026 | none |
| Mar 4, 2026 | GERARDO P HERNANDEZ Officer | 7,236 0.02% of outstanding | $1.1M | Mar 4, 2026 | none |
| Mar 4, 2026 | STEPHANIE LOVELL Director | 1,193 0.00% of outstanding | $178k | Mar 4, 2026 | none |
| Mar 4, 2026 | DAVID WEILL Director | 3,571 0.01% of outstanding | $524k | Mar 4, 2026 | none |
| Dec 3, 2025 | DAVID WEILL Director | 5,000 0.01% of outstanding | $693k | Dec 3, 2025 | none |
| Nov 25, 2025 | ANIL P RANGANATH Officer | 3,000 0.01% of outstanding | $436k | Nov 25, 2025 | none |
| Oct 29, 2025 | EDWARD BASILE Director | 4,142 0.01% of outstanding | $540k | Oct 29, 2025 | $520k |
| Aug 4, 2025 | EDWARD BASILE Director | 4,143 0.01% of outstanding | $520k | Aug 4, 2025 | $1.3M |
| May 27, 2025 | EDWARD BASILE Director | 5,000 0.01% of outstanding | $632k | May 27, 2025 | $694k |
| May 23, 2025 | DAVID WEILL Director | 732 0.00% of outstanding | $91k | May 23, 2025 | none |
| May 9, 2025 | EDWARD BASILE Director | 6,000 0.02% of outstanding | $694k | May 9, 2025 | none |
| Mar 4, 2025 | Gordon Stephen Officer | 5,942 0.02% of outstanding | $390k | Mar 4, 2025 | none |
| Nov 5, 2024 | EDWARD BASILE Director | 6,750 0.02% of outstanding | $564k | Nov 5, 2024 | $1.0M |
| Nov 1, 2024 | Tamer Khayal Officer | 7,625 0.02% of outstanding | $625k | Nov 1, 2024 | $911k |
| Jun 5, 2024 | Basile Edward M Director | 1,193 0.00% of outstanding | $165k | Jun 5, 2024 | $930k |
| Jun 3, 2024 | Gordon Stephen Officer | 2,060 0.01% of outstanding | $280k | Jun 3, 2024 | $7.3M |
| May 29, 2024 | Gordon Stephen Officer | 20,000 0.06% of outstanding | $2.7M | May 29, 2024 | $169k |
| May 29, 2024 | Weill David Director | 1,193 0.00% of outstanding | $169k | May 29, 2024 | $325k |
| May 10, 2024 | Weill David Director | 2,500 0.01% of outstanding | $327k | May 10, 2024 | none |
| May 7, 2024 | EDWARD BASILE Director | 7,157 0.02% of outstanding | $930k | May 7, 2024 | none |
| May 6, 2024 | Corcoran Nicholas Officer | 3,222 0.01% of outstanding | $419k | May 6, 2024 | none |
| May 6, 2024 | Gordon Stephen Officer | 15,000 0.05% of outstanding | $1.9M | May 6, 2024 | $2.5M |
| May 2, 2024 | Hassanein Waleed H Officer | 12,444 0.04% of outstanding | $1.5M | May 2, 2024 | $8.0M |
| May 1, 2024 | Waleed H. Hassanein Director, Officer | 84,625 0.26% of outstanding | $9.3M | May 1, 2024 | $1.5M |
| May 1, 2024 | Tamer Khayal Officer | 75,017 0.23% of outstanding | $8.1M | May 1, 2024 | $4.1M |
Transactions
The newest 50 of 335 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | David Weill director | POpen-market purchase Common Stock | +1,336 | $81.63 | $109k | 16,392 | 30 d ago |
| Aug 17, 2026 | James R Tobin director | GGift Common Stockindirect: By The Tobin 2024 Family Trust | -18,000 | $0.00 | $0 | 0 | Aug 17, 2026 |
| Jul 10, 2026 | Gerardo Hernandez Chief Financial Officer | AGrant or award Common Stock | +17,246 | $0.00 | $0 | 31,935 | Jul 14, 2026 |
| Jul 10, 2026 | Nicholas Corcoran See remarks | AGrant or award Common Stock | +11,727 | $0.00 | $0 | 41,558 | Jul 14, 2026 |
| Jul 10, 2026 | Waleed H Hassanein President & CEO | AGrant or award Common Stock | +49,669 | $0.00 | $0 | 171,093 | Jul 14, 2026 |
| Jul 10, 2026 | Gerardo Hernandez Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +26,153 | $0.00 | $0 | 26,153 | Jul 14, 2026 |
| Jul 10, 2026 | Nicholas Corcoran See remarks | AGrant or award Stock Option (Right to Buy)derivative | +17,784 | $0.00 | $0 | 17,784 | Jul 14, 2026 |
| Jul 10, 2026 | Waleed H Hassanein President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +112,984 | $0.00 | $0 | 112,984 | Jul 14, 2026 |
| Jun 15, 2026 | Thomas James Gunderson director | MOption exercise Common Stock | +19,285 | $2.21 | $43k | 26,266 | Jun 17, 2026 |
| Jun 15, 2026 | Thomas James Gunderson director | SOpen-market sale Common Stock | -9,624 | $75.06 | $722k | 16,642 | Jun 17, 2026 |
| Jun 15, 2026 | Thomas James Gunderson director | MOption exercise Stock Option (Right to Buy)derivative | -19,285 | $0.00 | $0 | 0 | Jun 17, 2026 |
| May 20, 2026 | Edwin M Kania Jr director | AGrant or award Common Stock | +2,922 | $0.00 | $0 | 263,732 | May 22, 2026 |
| May 20, 2026 | James R Tobin director | AGrant or award Common Stock | +2,922 | $0.00 | $0 | 6,981 | May 22, 2026 |
| May 20, 2026 | David Weill director | AGrant or award Common Stock | +2,922 | $0.00 | $0 | 15,056 | May 22, 2026 |
| May 20, 2026 | Merilee Raines director | AGrant or award Common Stock | +2,922 | $0.00 | $0 | 6,981 | May 22, 2026 |
| May 20, 2026 | Edward M Basile director | AGrant or award Common Stock10b5-1 | +2,922 | $0.00 | $0 | 5,788 | May 22, 2026 |
| May 20, 2026 | Thomas James Gunderson director | AGrant or award Common Stock | +2,922 | $0.00 | $0 | 6,981 | May 22, 2026 |
| May 20, 2026 | Stephanie Lovell director | AGrant or award Common Stock | +2,922 | $0.00 | $0 | 5,788 | May 22, 2026 |
| May 19, 2026 | Matthew S. Forsyth See Remarks | AGrant or award Common Stock | +15,409 | $0.00 | $0 | 15,409 | May 21, 2026 |
| May 19, 2026 | Matthew S. Forsyth See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +23,171 | $0.00 | $0 | 23,171 | May 21, 2026 |
| Mar 4, 2026 | Stephanie Lovell director | SOpen-market sale Common Stock | -1,193 | $149.62 | $178k | 2,866 | Mar 6, 2026 |
| Mar 4, 2026 | David Weill director | MOption exercise Common Stock | +3,571 | $14.20 | $51k | 15,705 | Mar 6, 2026 |
| Mar 4, 2026 | David Weill director | SOpen-market sale Common Stock | -3,571 | $146.82 | $524k | 12,134 | Mar 6, 2026 |
| Mar 4, 2026 | David Weill director | MOption exercise Stock Option (Right to Buy)derivative | -3,571 | $0.00 | $0 | 1,429 | Mar 6, 2026 |
| Mar 2, 2026 | Gerardo Hernandez Chief Financial Officer | SOpen-market sale Common Stock | -375 | $139.12 | $52k | 14,689 | Mar 4, 2026 |
| Mar 2, 2026 | Anil P. Ranganath See remarks | SOpen-market sale Common Stock | -864 | $139.12 | $120k | 13,091 | Mar 4, 2026 |
| Jan 23, 2026 | Nicholas Corcoran See remarks | FTax withholding Common Stock | -984 | $135.30 | $133k | 32,797 | Mar 4, 2026 |
| Mar 4, 2026 | Gerardo Hernandez Chief Financial Officer | MOption exercise Common Stock | +1,324 | $77.12 | $102k | 16,013 | Mar 4, 2026 |
| Mar 2, 2026 | Nicholas Corcoran See remarks | SOpen-market sale Common Stock | -2,966 | $139.12 | $413k | 29,831 | Mar 4, 2026 |
| Mar 4, 2026 | Gerardo Hernandez Chief Financial Officer | SOpen-market sale Common Stock | -1,324 | $147.21 | $195k | 14,689 | Mar 4, 2026 |
| Mar 4, 2026 | Gerardo Hernandez Chief Financial Officer | MOption exercise Common Stock | +5,912 | $69.84 | $413k | 20,601 | Mar 4, 2026 |
| Mar 4, 2026 | Gerardo Hernandez Chief Financial Officer | SOpen-market sale Common Stock | -5,912 | $147.21 | $870k | 14,689 | Mar 4, 2026 |
| Mar 4, 2026 | Gerardo Hernandez Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -1,324 | $0.00 | $0 | 3,975 | Mar 4, 2026 |
| Mar 4, 2026 | Gerardo Hernandez Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -5,912 | $0.00 | $0 | 13,010 | Mar 4, 2026 |
| Feb 18, 2026 | Giovanni Cecere Chief Commercial Officer | AGrant or award Common Stock | +11,082 | $0.00 | $0 | 19,057 | Feb 20, 2026 |
| Feb 18, 2026 | Giovanni Cecere Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +16,734 | $0.00 | $0 | 16,734 | Feb 20, 2026 |
| Dec 4, 2025 | Gerardo Hernandez Chief Financial Officer | SOpen-market sale Common Stock | -920 | $139.62 | $128k | 15,064 | Dec 5, 2025 |
| Dec 3, 2025 | David Weill director | MOption exercise Common Stock | +5,000 | $14.20 | $71k | 17,134 | Dec 5, 2025 |
| Dec 3, 2025 | David Weill director | SOpen-market sale Common Stock | -5,000 | $138.64 | $693k | 12,134 | Dec 5, 2025 |
| Dec 3, 2025 | David Weill director | MOption exercise Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 5,000 | Dec 5, 2025 |
| Nov 25, 2025 | Anil P. Ranganath See remarks | MOption exercise Common Stock | +3,000 | $93.88 | $282k | 16,955 | Nov 26, 2025 |
| Nov 25, 2025 | Anil P. Ranganath See remarks | SOpen-market sale Common Stock | -3,000 | $145.22 | $436k | 13,955 | Nov 26, 2025 |
| Nov 25, 2025 | Anil P. Ranganath See remarks | MOption exercise Stock Option (Right to Buy)derivative | -3,000 | $0.00 | $0 | 7,420 | Nov 26, 2025 |
| Nov 17, 2025 | Waleed H Hassanein President & CEO | POpen-market purchase Common Stockindirect: By the Waleed H. Hassanein Revocable Trust | +8,775 | $114.00 | $1.0M | 495,009 | Nov 18, 2025 |
| Oct 29, 2025 | Edward M Basile director | MOption exercise Common Stock10b5-1 | +4,142 | $0.70 | $2,899 | 7,008 | Oct 31, 2025 |
| Oct 29, 2025 | Edward M Basile director | SOpen-market sale Common Stock10b5-1 | -4,142 | $130.45 | $540k | 2,866 | Oct 31, 2025 |
| Oct 29, 2025 | Edward M Basile director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,142 | - | - | 0 | Oct 31, 2025 |
| Aug 6, 2025 | Waleed H Hassanein President & CEO | POpen-market purchase Common Stockindirect: By the Waleed H. Hassanein Revocable Trust | +8,400 | $118.68 | $997k | 477,759 | Aug 8, 2025 |
| Aug 7, 2025 | Waleed H Hassanein President & CEO | POpen-market purchase Common Stockindirect: By the Waleed H. Hassanein Revocable Trust | +6,617 | $116.08 | $768k | 484,376 | Aug 8, 2025 |
| Aug 7, 2025 | Waleed H Hassanein President & CEO | POpen-market purchase Common Stockindirect: By the Waleed H. Hassanein Revocable Trust | +1,858 | $116.85 | $217k | 486,234 | Aug 8, 2025 |
50 of 335 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Edward M Basiledirector
- Giovanni CecereChief Commercial Officer
- Nicholas CorcoranSee Remarks
- Matthew S. ForsythSee Remarks
- Stephen GordonChief Financial Officer
- Thomas James Gundersondirector
- Waleed H HassaneinPresident & CEO
- Gerardo HernandezChief Financial Officer
- Edwin M Kania Jrdirector
- Tamer I KhayalChief Commercial Officer
- Stephanie Lovelldirector
- Merilee Rainesdirector
- Anil P. RanganathSee remarks
- James R Tobindirector
- David Weilldirector
Questions about TMDX
Answered from the filings on this page, as of the latest one.
Are insiders buying TMDX?
As of Sep 14, 2026, SEC Form 4 filings show 1 open-market buy worth $109k by 1 insider and 0 open-market sells worth $0 by 0 insiders at TransMedics Group, Inc. in the last 90 days, net +$109k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade TMDX on the open market?
David Weill (director) bought $109k of TMDX on Sep 11, 2026 and filed the Form 4 on Sep 14, 2026. InsiderTell scored 36 (weak).
How many insiders file Form 4 at TransMedics Group, Inc.?
15 people have filed a Form 4 at TransMedics Group, Inc., among them Edward M Basile (director), Giovanni Cecere (Chief Commercial Officer), Nicholas Corcoran (See Remarks). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.